These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 15976780)

  • 1. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
    Giugliano RP; Newby LK; Harrington RA; Gibson CM; Van de Werf F; Armstrong P; Montalescot G; Gilbert J; Strony JT; Califf RM; Braunwald E;
    Am Heart J; 2005 Jun; 149(6):994-1002. PubMed ID: 15976780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
    Stone GW; Bertrand M; Colombo A; Dangas G; Farkouh ME; Feit F; Lansky AJ; Lincoff AM; Mehran R; Moses JW; Ohman M; White HD
    Am Heart J; 2004 Nov; 148(5):764-75. PubMed ID: 15523305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial.
    Wang TY; White JA; Tricoci P; Giugliano RP; Zeymer U; Harrington RA; Montalescot G; James SK; Van de Werf F; Armstrong PW; Braunwald E; Califf RM; Newby LK
    Circulation; 2011 Feb; 123(7):722-30. PubMed ID: 21300952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of patients with non-ST-segment elevation acute coronary syndromes: insights from the PURSUIT trial.
    Fintel DJ; Ledley GS
    Clin Cardiol; 2000 Sep; 23 Suppl 5(Suppl 5):V1-12. PubMed ID: 11019716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of eptifibatide in patients undergoing percutaneous coronary intervention.
    Zeymer U
    Expert Opin Pharmacother; 2007 Jun; 8(8):1147-54. PubMed ID: 17516878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial.
    Fitchett DH; Langer A; Armstrong PW; Tan M; Mendelsohn A; Goodman SG;
    Am Heart J; 2006 Feb; 151(2):373-9. PubMed ID: 16442903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
    Tricoci P; Newby LK; Hasselblad V; Kong DF; Giugliano RP; White HD; Théroux P; Stone GW; Moliterno DJ; Van de Werf F; Armstrong PW; Prabhakaran D; Rasoul S; Bolognese L; Durand E; Braunwald E; Califf RM; Harrington RA
    Circ Cardiovasc Qual Outcomes; 2011 Jul; 4(4):448-58. PubMed ID: 21712522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early versus delayed, provisional eptifibatide in acute coronary syndromes.
    Giugliano RP; White JA; Bode C; Armstrong PW; Montalescot G; Lewis BS; van 't Hof A; Berdan LG; Lee KL; Strony JT; Hildemann S; Veltri E; Van de Werf F; Braunwald E; Harrington RA; Califf RM; Newby LK;
    N Engl J Med; 2009 May; 360(21):2176-90. PubMed ID: 19332455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators.
    Hasdai D; Holmes DR; Criger DA; Topol EJ; Califf RM; Wilcox RG; Paolasso E; Simoons M; Deckers J; Harrington RA
    Am Heart J; 2000 Mar; 139(3):454-60. PubMed ID: 10689260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
    Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators
    N Engl J Med; 1998 Aug; 339(7):436-43. PubMed ID: 9705684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
    Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML
    Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
    Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM;
    Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial.
    Labinaz M; Kaul P; Harrington RA; Chang WC; Kleiman NS; Simoons ML; Boersma E; Akkerhuis KM; Califf RM; Armstrong PW;
    Can J Cardiol; 2004 Jun; 20(8):773-8. PubMed ID: 15229770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial.
    Goodman S
    Am Heart J; 2005 Apr; 149(4 Suppl):S73-80. PubMed ID: 16124951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial.
    Bagai A; White JA; Lokhnygina Y; Giugliano RP; Van de Werf F; Montalescot G; Armstrong PW; Tricoci P; Gibson CM; Califf RM; Harrington RA; Newby LK
    Am Heart J; 2013 Sep; 166(3):466-73. PubMed ID: 24016495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome.
    De Servi S; Mariani M; Vandoni P; Dellavalle A; Politi A; Poletti F; Bonizzoni E; Leoncinie M;
    J Cardiovasc Med (Hagerstown); 2006 Mar; 7(3):159-65. PubMed ID: 16645379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial).
    Kunadian V; Giugliano RP; Newby LK; Zorkun C; Guo J; Bagai A; Montalescot G; Braunwald E; Califf RM; Van de Werf F; Armstrong PW; Harrington R; Gibson CM
    Am J Cardiol; 2014 Apr; 113(8):1297-305. PubMed ID: 24607027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
    Stone GW; Bertrand ME; Moses JW; Ohman EM; Lincoff AM; Ware JH; Pocock SJ; McLaurin BT; Cox DA; Jafar MZ; Chandna H; Hartmann F; Leisch F; Strasser RH; Desaga M; Stuckey TD; Zelman RB; Lieber IH; Cohen DJ; Mehran R; White HD;
    JAMA; 2007 Feb; 297(6):591-602. PubMed ID: 17299194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial.
    Steg PG; Mehta SR; Pollack CV; Bode C; Cohen M; French WJ; Hoekstra J; Rao SV; Ruzyllo W; Ruiz-Nodar JM; Sabaté M; Widimsky P; Kiss RG; Navarro Estrada JL; Hod H; Kerkar P; Guneri S; Sezer M; Ruda M; Nicolau JC; Cavallini C; Ebrahim I; Petrov I; Kim JH; Jeong MH; Ramos Lopez GA; Laanmets P; Kovar F; Gaudin C; Fanouillere KC; Minini P; Hoffman EB; Moryusef A; Wiviott SD; Sabatine MS;
    JAMA; 2013 Sep; 310(11):1145-55. PubMed ID: 23995608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.